Patient characteristics, drug adherence patterns, and hypoglycemia costs for patients with type 2 diabetes mellitus newly initiated on exenatide or insulin glargine
Patient characteristics, drug adherence patterns, and hypoglycemia costs for patients with type 2 diabetes mellitus newly initiated on exenatide or insulin glargine
复制标题
DOI：
10.1185/03007990802715199
复制
发表时间：
2009-03-01
影响因子：
2.3
通讯作者：
Wade, Ron
中科院分区：
文献类型：
--
作者：
Fabunmi, Rosalind;Nielsen, Loretta L.;Wade, Ron
目的：检查新开始服用艾塞那肽或甘精胰岛素的 2 型糖尿病患者的实际有效性和低血糖成本负担。设计和方法：回顾性队列研究，使用管理索赔数据库描述患者特征、药物依从模式和 1 年低血糖率以及相关成本。患有 2 型糖尿病的成年受试者在 2005 年 5 月 1 日至 2007 年 6 月 30 日期间首次申请艾塞那肽或甘精胰岛素，并且在开始前≥ 6 个月和开始后≥ 12 个月具有持续资格。 结果：艾塞那肽队列 (n=3262) 年龄为 53 +/- 10 年 (+/-SD)； 54%为女性。甘精胰岛素队列 (n=3038) 年龄为 56 +/- 12 岁； 41%为女性。艾塞那肽的平均 Deyo-Charlson 合并症指数评分为 1.45，而甘精胰岛素的平均 Deyo-Charlson 合并症指数评分为 1.82（p
Objective: Examine real-world effectiveness and hypoglycemia cost burden in patients with type 2 diabetes newly initiated on exenatide or insulin glargine.Design and methods: Retrospective cohort study describing patient characteristics, drug adherence patterns, and 1-year hypoglycemia rates with associated costs using an administrative claims database. Adult subjects with type 2 diabetes had an initial claim for exenatide or insulin glargine between May 1, 2005 and June 30, 2007, and had continuous eligibility for >= 6 months pre- and >= 12 months post-initiation.Results: The exenatide cohort (n=3262) was 53 +/- 10 years (+/-SD); 54% female. The insulin glargine cohort (n=3038) was 56 +/- 12 years; 41% female. The mean Deyo-Charlson comorbidity index score was 1.45 for exenatide versus 1.82 for insulin glargine (p